MedTrace Logo

Efficacy and Safety of Tetrabenazine in Chorea

NCT00219804 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2005-09-22

No results posted yet for this study

Summary

The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo

Conditions

Interventions

DRUG

tetrabenazine or placebo

Sponsors & Collaborators

  • Prestwick Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Fred Marshall, M.D. · Huntington's Study Group

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219804 on ClinicalTrials.gov